Vivos Therapeutics, a medical technology company specializing in treatment alternatives for patients with dentofacial abnormalities and sleep apnea, reported a decrease in revenue for the first quarter of 2024. Total revenue fell by 11% to $3.4 million compared to $3.9 million in the same period of the previous year. This decline was attributed to a $98,000 drop in product revenue and a $340,000 decrease in service revenue. The company's net loss widened to $3.8 million from $1.7 million year-over-year. Operating expenses decreased by 25% to $4.9 million, primarily due to reduced professional fees and personnel costs following a reduction in force. Despite cost-saving measures and reduced cash used in operations, Vivos Therapeutics acknowledged the need for additional financing to sustain operations and comply with Nasdaq's minimum stockholders' equity requirement. The company's cash and cash equivalents stood at $2.6 million as of March 31, 2024. Vivos Therapeutics continues to implement a remediation plan to address material weaknesses in internal control over financial reporting, with progress expected throughout 2024.

Vivos Therapeutics, a medical technology company specializing in treatment alternatives for patients with dentofacial abnormalities and sleep apnea, reported a decrease in revenue for the first quarter of 2024. Total revenue fell by 11% to $3.4 million compared to $3.9 million in the same period of the previous year. This decline was attributed to a $98,000 drop in product revenue and a $340,000 decrease in service revenue. The company's net loss widened to $3.8 million from $1.7 million year-over-year. Operating expenses decreased by 25% to $4.9 million, primarily due to reduced professional fees and personnel costs following a reduction in force. Despite cost-saving measures and reduced cash used in operations, Vivos Therapeutics acknowledged the need for additional financing to sustain operations and comply with Nasdaq's minimum stockholders' equity requirement. The company's cash and cash equivalents stood at $2.6 million as of March 31, 2024. Vivos Therapeutics continues to implement a remediation plan to address material weaknesses in internal control over financial reporting, with progress expected throughout 2024.